Moxifloxacin: A respiratory fluoroquinolone

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 10, 2008, Pages 1755-1772

  Miravitlles, Marc ^a   Anzueto, Antonio ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Chronic bronchitis; Community acquired pneumonia; Moxifloxacin; Quinolones; Rhinosinusitis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; HALOFANTRINE; LEVOFLOXACIN; MACROLIDE; MIZOLASTINE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PENICILLIN DERIVATIVE; PENTAMIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TERFENADINE; TETRACYCLINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; TROVAFLOXACIN; UNINDEXED DRUG;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; HEART DISEASE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PRIMARY HEALTH CARE; RESPIRATORY TRACT INFECTION; RHINOSINUSITIS; SINGLE DRUG DOSE; SYMPTOM; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BRONCHITIS, CHRONIC; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; QUINOLINES; RESPIRATORY TRACT INFECTIONS; SINUSITIS;

EID: 48049084950     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.10.1755     Document Type: Article

References (107)

1. Miravitlles M, Murio C, Guerrero T, Gisbert R; on Behni of the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55
2. MacFarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001;56:109-14
3. Doll H, Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005;23:345-63
4. Sobradillo V, Miravitlles M, Gabriel R, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981-9
5. Loddenkemper R, Editor in Chief. The European Lung White Book. European Respiratory Society; 2003
6. Huchon GJ, Vergnenègre A, Neukirch F, et al. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J 2002;20:806-12
7. De Marco R, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004;59:120-5
8. Cerveri I, Accordini S, Verlato G, et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001;18:85-92
9. Celli BR, MacNee W and Committee Members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
10. Jemal A, Ward E, Han Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-9
11. Miravitlles M, Murio C, Guerrero T, Gisbert R; On Behalf of the DAFNE Study Group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest 2003;123:784-91
12. Miravitlles M, Anzueto A, Legnani D, et al. Patienes perception of exacerbations of COPD - the PERCEIVE study. Respir Med 2007;101:453-60
13. Seemungal TAR, Donaldson GC, Paul FA. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-22
14. Miravitlles M, Ferrer M, Pont A, et al. for the IMPAC study group: exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax 2004;59:387-95
15. Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 2002;9:191-7
16. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21
17. Halls GA. The management of infections and antibiotic therapy: a European survey. J Antimicrob Chemother 1993;31:985-1000
18. Smith JA, Redman P, Woodhead MA. Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999;13:835-8
19. Chodosh S. Role of antimicrobials in chronic bronchitis. Infect Med 1999;16:8-20
20. Felmingham D, Gruneberg RN. The Alexander Project 1996 - 1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45:191-203
21. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835-42
22. Miravitlles M, Mayordomo, C, Artés M, et al. on behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999;93:173-9
23. Bjerrum L, Boada A, Cots JM, et al. Respiratory tract infections in general practice: considerable differences in prescribing habits between general practitioners in Denmark and Spain. Eur J Clin Pharmacol 2004;60:23-8
24. Blondeau J. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob, Chemother 1999;43:1-11
25. Jones ME, Salun DF, Martin N, et al. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob, Agents Chemother 2000;44:462-6
26. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother 2002;46:522-4
27. Saravolatz L, Manzor O, Check C, et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001;47:875-77
28. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999;44:835-8
29. Miravitlles M. Moxifloxacin: an antibiotic designed for use in the community. Eur Respir Rev 2000;10:161-9
30. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001;47:811-8
31. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral amoxicillin-clavulanate with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-54
32. Klossek JM, Siegert R, Nikolaidis P, et al. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusids in adults. J Laryngol Otol 2003;117(1):43-51
33. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-3
34. Miravitlles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005;6:283-93
35. Llor C, Cots JM, Boada A, et al.; Grupo cle estudio AUDITINF02. Variability of antibiotic prescribing for respiratory tract infections in two European countries. Enferm Infecc Microbiol Clin 2005;23:598-604
36. Goossens H, Ferech M, Stichele RV, Elseviers M; for the ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87
37. Petersen I, Johnson AM, Islam A, et al. Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. BMJ 2007;335:982-7
38. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80
39. ALAT Work Group. Update to the Latin American Thoracic Society (ALAT) recommendations on infectious exacerbation of COPD. Arch Bronconeumol 2004;40:315-25
40. ALAT Work Group. Update to the Latin American Thoracic Society (ALAT) recommendations on community-acquired pneumonia. Arch Bronconeumol 2004;40:364-74
41. Miravitlles M, Monsó E, Mensa J, et al. Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch Bronconeumol 2008;44:100-9
42. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72
43. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 2005;49:153-60
44. Martinez FJ, Grossman RF, Zadeikis N, et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur Respir J 2005;25:1001-10
45. Martinez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int J Antimicrob Agents 2005;26(Suppl 3):S156-63
46. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433-8
47. Dalhoff A, Petersen U, Endennann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996;42:410-25
48. Scheld VM. Maintaining fluoroquinolone efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9
49. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001;32(Suppl 1):S51-63
50. Woodcock JM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997;41:101-6
51. Stass H, Kubitza D, Schühly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001;40(Suppl 1):1-9
52. Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (BAY 12-8039), a new enantiomerically pure 8-methoxyquinolone. Antimicrob Agents Chemother 1999;43:2793-7
53. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002;53:232-7
54. Stan H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001;32(Suppl 1):S47-50
55. Schentag J, Nix DE, Forrest A, et al. AUIC - the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996;30:1024-8
56. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81
57. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J COPD 2007;2:191-204
58. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone and its potential relation to therapeutic efficacy. Clin Drug Invest 1999;17:365-87
59. Niederman MS, Anzueto A, Sethi S, et al. Eradication of H. influenzae. in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 2006;100:1781-90
60. Miravitlles M, Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest 2004;125:811-3
61. Dewan NA, Rafique S, KanWAR B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000;117:662-7
62. Miravitlles M, Murio C, Guerrero T; On Behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur Respir J 2001;17:928-33
63. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004;125:953-64
64. Wilson R, Jones P, Schaberg T, et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006;61:337-42
65. Miravitlles M, Molina J, Brosa M. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and metaanalysis. Arch Bronconeumol 2007;43:16-21
66. Schaberg T, Ballin I, Huchon G, et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with amoxicillin-clavulanate oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001;29:314-28
67. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003;3:359-71
68. De Benedetto F, Sevieri G. Chronic obstructive pulmonary disease (COPD) exacerbation and inflammation of the respiratory tract: clinical implication, prognostic consequences, and therapeutic strategies. Multidisciplin Respir Med 2006;1:36-48
69. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005;127:2231-6
70. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002:20(Suppl 36):9s-19s
71. Chodosh S, Schreurs A, Siami G, et al. The efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998;27:730-8
72. Sethi S, Anzueto A, Wilson R, et al. Placebo-controlled, double-blind trial of chronic, intermittent "pulse" therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data. Eur Respir J 2006;(Suppl 50)-A810
73. Kreis SR, Herrera N, Golzar N, et al. A comparison of moxifloxacin and azithromycin in the treament of acute exacerbations of chronic bronchitis. J Clin Outcomes Manage 2000;7:33-7
74. Miravitlles M, Zalacain R, Murio C, et al.; On Behalf of the IMPAC Study Group. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two-year study. Clin Drug Invest 2003;23:439-50
75. Miravitlles M, Llor C, Naberan K, et al.; for the EFEMAP Study Group. The effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary discase in primary care. Clin Drug Invest 2004;24:63-72
76. Miravitlles M, Llor C, Naberan K, et al. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 2005;99:955-65
77. Llor C, Naberan K, Cots JM, et al. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care centers. Int J Clin Pract 2004;58:937-44
78. Welte T, Petermann W, Schuermann D, et al.; and the MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005;41:1697-705
79. Petitpretz P, Arvis P, Marel M, et al.; for the CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-95
80. Jardim JR, Rico G, De La Roza C, et al.; and the Group of Latin-American Study CAP5. Comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial. Arch Bronconeumol 2003;39:387-93
81. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-43
82. Anzueto A, Niederman MS, Pearle J, et al.; for the Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006;42:73-81
83. Morganroth J, DiMarco JP, Anzueto A, et al.; and the CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs. levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128:3398-406
84. Torres A, Garau J, Arvis P, et al. MOTIV (MOxifloxacin Treatment IV) Study Group. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial. Clin Infect Dis 2008;46:1499-509
85. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po amoxicillin-clavulanate with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124:526-35
86. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000;94:337-44
87. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004;26:940-50
88. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. Symp Ser Soc Appl Microbiol 2002;31(Suppl):55-64
89. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003;52:944-52
90. Davies TA, Goldschmidt R, Pfleger S, et al. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae 1998-2000. J Antimicrob Chemother 2003;52:168-75
91. Hesje CK, Tillotson GS, Blondeau, JM. MICs, MPDs and PK/PDs: a match (sometimes) made in hosts. Expert Rev Respir Med 2007;1:7-16
92. Richter A, Anton SF, Koch P, Deanett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35
93. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal penumonia. N Engl J Med 2002;346:747-50
94. Startton CW. Dead bugs don't mutate. Susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis [serial online] 2003;8. Available from: http://www.cdc.gov/ncidod/EID/vol9nol/ 02-1075.htm [Last accessed 19 May 2008]
95. Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis 2007;1:61-76
96. Chodosh S, De Abate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000;94:18-27
97. De Abate CA, Mathew CP, Warner JH, et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000;94:1029-37
98. Grassi C, Casali L, Curti E, et al.; for the SMART Study Group. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002;14:597-608
99. Landen H, Möller M, Tillotson GS, et al. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001;29:51-60
100. Lorenz J, Busch W, Thate-Waschke I-M, et al. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res 2001;29:61-73
101. Miravitlles M, Ros F, Cobos A, et al. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int J Clin Pract 2001;55:437-44
102. Zervos M, Martinez FJ, Amsden QW, et al. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents 2007;29:56-61
103. Miravitlles M, Llor C. Determining factors in the prescription of a fluorquinolone, moxifloxacin, in exacerbations of chronic bronchitis in the primary care setting. Clin Drug Invest 2007;27:95-104
104. Hoeffken G, Meyer HP, Winter J, Verhoef 1, for the CAPI Study Group. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-64
105. Patel T, Pearl J, William J, et al. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community-acquired Pneumonia Study Group. Respir Med 2000;94:97-105
106. Hautamaki D, Bruya T, Kureishi A, et al. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Today's Therapeutic Trends 2001;19:117-36.
107. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2004;23:129-37.